Neumora Therapeutics (NASDAQ:NMRA) Stock Rating Lowered by Guggenheim

Neumora Therapeutics (NASDAQ:NMRA) was downgraded by investment analysts at Guggenheim from a “buy” rating to a “neutral” rating in a research report issued to clients and investors on Friday, MarketBeat reports.

Several other equities research analysts also recently issued reports on the company. Needham & Company LLC restated a “buy” rating and set a $5.00 price objective on shares of Neumora Therapeutics in a report on Tuesday, March 4th. HC Wainwright lowered their target price on Neumora Therapeutics from $30.00 to $18.00 and set a “buy” rating for the company in a report on Tuesday, March 4th. Bank of America lowered their price target on shares of Neumora Therapeutics from $22.00 to $7.00 and set a “buy” rating for the company in a research report on Monday, January 6th. William Blair restated an “outperform” rating on shares of Neumora Therapeutics in a research report on Wednesday, January 15th. Finally, Royal Bank of Canada reissued a “sector perform” rating and set a $4.00 target price on shares of Neumora Therapeutics in a research note on Tuesday, March 4th. Four analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $10.14.

Neumora Therapeutics Price Performance

NASDAQ:NMRA opened at $1.49 on Friday. Neumora Therapeutics has a 1-year low of $1.30 and a 1-year high of $18.61. The firm has a 50 day simple moving average of $2.44 and a 200-day simple moving average of $8.61. The firm has a market cap of $240.73 million, a PE ratio of -0.80 and a beta of 2.59.

Neumora Therapeutics (NASDAQ:NMRA) last posted its earnings results on Thursday, March 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.09. As a group, sell-side analysts expect that Neumora Therapeutics will post -1.61 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Neumora Therapeutics

Institutional investors have recently bought and sold shares of the business. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Neumora Therapeutics during the 4th quarter worth approximately $61,000. PNC Financial Services Group Inc. bought a new stake in Neumora Therapeutics during the 4th quarter worth about $64,000. Quantbot Technologies LP bought a new stake in shares of Neumora Therapeutics during the fourth quarter valued at approximately $92,000. PEAK6 LLC bought a new position in Neumora Therapeutics in the 4th quarter valued at $117,000. Finally, EntryPoint Capital LLC acquired a new stake in Neumora Therapeutics in the fourth quarter worth about $135,000. Institutional investors and hedge funds own 47.65% of the company’s stock.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.